Sandbox:haytham1: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 32: | Line 32: | ||
==chemotherapy== | ==chemotherapy== | ||
===hi=== | |||
Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 17p deletion]] | Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 17p deletion]] | ||
Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 11q deletion]] | Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 11q deletion]] | ||
Immunochemotherapeutic regimens for management of patients '''without''' [[#Chemotherapy|chromosome 17p deletion]] or [[#Chemotherapy|chromosome 11q deletion]] | Immunochemotherapeutic regimens for management of patients '''without''' [[#Chemotherapy|chromosome 17p deletion]] or [[#Chemotherapy|chromosome 11q deletion]] | ||
Revision as of 16:05, 16 October 2015
Initial patients evaluation | |||||||||||||||||||||||||||||||||||||||||||||||||
History Physical examination Complete blood count | |||||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai Staging System Binet Staging System | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai stage 3-4 Binet stage B-C | Rai stage 0-2 Binet stage A | ||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate patients by cumulative index illness rating scale | Patients managed by observation and close follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||
Frail patients (CIRS ≥6) | Fit patients (CIRS <6) | ||||||||||||||||||||||||||||||||||||||||||||||||
Retixumab/obinutuzumab AND chlorambucil | FISH chromosomal analysis | ||||||||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion here | Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion | Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion | |||||||||||||||||||||||||||||||||||||||||||||||
Patients Age | |||||||||||||||||||||||||||||||||||||||||||||||||
Age <70 years | Age ≥70 years | ||||||||||||||||||||||||||||||||||||||||||||||||
chemotherapy
hi
Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion